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por years, cardiac imaging centers across the
U.S. have enjoyed tremendous success, with
growth rates frequently exceeding 10% per
year (1,2). These years of prosperity were
pawned by an abundance of evidence on a high
egree of published diagnostic accuracy as well as
ata on risk assessment in diverse patient popula-
ions (3–8). Heretofore, cardiac imaging had
ever enjoyed such a prominent and expansive
ody of evidence as to the role of imaging modal-
ties, such as echocardiography or myocardial per-
usion single-photon emission computed tomog-
aphy (SPECT), to guide patient management.
his growth in cardiac imaging occurred concur-
ently with and perhaps impacted upon declining
ardiovascular morbidity and mortality (9). Since
979, declines in coronary heart disease mortality
ave exceeded 30% within the U.S. population
9). Yet, the growth in cardiac imaging often out-
aced that of many other medical procedures
10). For example, the Medicare Payment Advi-
ory Commission reported in 2005 that imaging
rew at a rate nearly double that of other proce-
ures (10). For payers, growth in cardiac imaging
ncumbered an ever-increasing percentage of
ealth care spending. In 2003, Medicare pay-
ents for myocardial perfusion SPECT exceeded
1 billion, rendering it one of the “big ticket”
tems in the health care budget (AMA-RUC,
ersonal communication, 2006). New technology
evelopments in computed tomography (CT) and
agnetic resonance (MR) imaging, as well as the
nitial widespread purchase of this equipment na-
ionwide, prompted additional concern on the tart of payers as to the potential for further
nancially catastrophic growth rates in cardiac
maging.
Consequent to this, numerous efforts were put
orth in order to contain rising health care costs,
ncluding deficit reduction act–induced cuts in re-
mbursement as well as utilization management
trategies (e.g., pre-certification, radiology benefit
anagers). These payer initiatives were meant to
alt unrestrained use of imaging with a variable
ffect on accelerating health care costs. It should
e noted that for those of us within the cardio-
ascular medical community, it was not that im-
ging growth was the result of excess per se, but
hat the procedural volume could not be justified
r evaluated as appropriate. One message that
rose from the focus on imaging utilization was
hat the “true” nature of utilization, whether it be
nder-use or over-use, was unknown.
The Institute of Medicine roundtable on evidence-
ased medicine described contributing factors to
xcessive health care costs, including the rapid
ace of medical innovation outpacing the devel-
pment of appropriate or effective strategies for
se (11). The medical community has frequently
een left to render clinical decisions without the
enefit of appropriate study results or with data
hat has limited applicability to “real world” set-
ings. Thus, despite an abundance of high-quality
rognostic and diagnostic evidence, the growth in
maging utilization did not include evidence that
ould be used to evaluate and guide daily clinical
ractice decisions that impact the lives of our pa-
ients. An initial response led by the American
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267ollege of Cardiology (ACC) put forth criteria to
efine appropriate use of common cardiac imag-
ng procedures, such as myocardial perfusion
PECT (12), echocardiography (13), MR, and
T (14). The manifest destiny from the appro-
riateness criteria is that all imagers must be ac-
ive in the referral process to educate and guide
rimary care physicians on appropriate use of im-
ging modalities.
However, moving beyond the appropriateness cri-
eria, the ACC in combination with Duke Univer-
ity Cardiovascular Imaging Center held a think
ank, first held in 2006, to put forth a “road map”
or achieving quality in imaging (15); a follow-up
onference was held in October 2007. This issue of
ACC: Cardiovascular Imaging includes a CVN in-
erview with the Conference Chair, Pamela
ouglas, MD, MACC. Major goals of these 2
hink tank meetings have been to devise strategic
fforts to define and assure quality cardiac imag-
ng, including appropriate test selection. A central
heme in this year’s conference was to provide
angible and realistic structural and process indi-
ators of imaging health care quality. Quality
ealth care may be defined using a triad of factors
omposed within the structure or laboratory set-
ing (e.g., laboratory accreditation), processes of
est performance and within the episode of care
e.g., structured reporting), and outcome indica-
ors. For cardiac imaging, indicators of quality
esting include: appropriate test selection; labora-
ory, technologists, and physician subspecialty cer-
ification and training; as well as structured re-
orting. The ACC/Duke think tank also engaged
n discussion around this latter component of im-
roved patient outcome, a more difficult measure
o implement nationwide. Similar to the ACC’s
ational Cardiovascular Data Registry (NCDR)
or Cath/PCI, which has been instrumental in
evising procedural outcome standards for diag-
ostic coronary angiography and percutaneous
oronary interventional procedures (16), there has
een exploration of possible registries whose main
urpose would be to identify achievable, quality
ndicators as well as to provide support for appro-
riate test utilization with the goal to achieve op-
imal patient outcomes. This effort is part of a
ore global focus within medicine to devise moreatient-centric strategies of health care quality. expanding on evidence offered over the last few
ecades on diagnosis and risk assessment, any
rowth in cardiac imaging must now be justified
ith supportive data revealing improved patient
utcomes. These efforts on devising quality imag-
ng, spawned within the ACC/Duke think tank,
ave expanded to include the support and collab-
ration of all subspeciality societies within cardi-
logy, including the American Society of Echo-
ardiography and American Society of Nuclear
ardiology, as well as the American Heart Asso-
iation and the American College of Radiology.
Based on this think tank, what do we envision
or the future of cardiac imaging? The future of
ardiac imaging depends on forging locally based,
atient-centered “safety nets” to support imaging
ecisions and to evaluate medical management
ecisions. Thus, mandatory laboratory accredita-
ion will be a core mainstay for any imaging labo-
atory and will include continuing quality initia-
ives as a quality driver as well as the potential for
ata repositories to guide local quality initiatives.
oreover, image acquisition and interpretation
ill be standardized with efforts underway to
dentify higher-quality or “gold star” imagers. As
art of this effort, structured reporting is a key el-
ment to ensure adequate documentation and re-
aying of critical factors necessary for referring
hysicians to implement effective decisions based
n imaging risk markers.
As part of this plan, cardiovascular imagers must
ctively engage in the discussion about the future of
uality initiatives that seek to focus patient-centered
utcomes at the heart of imaging-driven care. This
s particularly true when the discussion includes
easurement of local outcomes derived from labora-
ory registries. It should be made manifest that prior
vidence included critical data on population test ef-
ectiveness. However, if we are to achieve patient-
riented interpretation with a goal that an added
est or referral within the patient work-up must im-
rove outcomes, then our evidence-base must now
ove beyond the research arena. As this discussion
nfolds, however, we believe that the arguments and
trategies must be realistic and provide iterative ap-
roaches to registry development so as to minimize
aboratory burden. This being said, the strategies
ust reflect how the test is used clinically and notmbark on overly ambitious projects requiring sub-
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268tantive local investments aimed at defining a net
mprovement in health outcomes, particularly within
he current environment of declining reimburse-
ent. In many cases, staff labor for patient enroll-
ent and source documentation for the ACC’s
CDR require substantial local investment that is,
n many cases, unrecouped. Similar strategies within
he less-experienced and higher-volume imaging
aboratories could have disastrous economic conse-
uences, with the net result being potentially unreli-
ble patient outcomes data. Given the expertise of
he ACC/Duke think tank leadership, one can be
ssured that the path forward will be measured.
As standards change within local laboratories, it
s clear that the culture of clinical research for
ardiac imaging must also evolve to be decidedly
ore expansive. Given our new standards of qual-
ty imaging, the necessary and sufficient evidence
ase for new technology must exceed the current,
inimal standards of diagnostic equivalence or
alidity. In today’s environment, the majority of
ur prognostic evidence arises from few academic
enters with little to no financial support for such
entures. Moreover, funding for cardiac imaging
esearch rarely approaches the investment placedACC/AHA 2002 guideline update for 114:1761–91.ls of quality imaging that we see for the future,
ndustry and governmental agencies must priori-
ize and invest in a global strategy for new imag-
ng technology that includes prognosis and cost
fficiency data from diverse patient series. A lack
f sufficient clinical outcomes data has hindered
ecent expansion for new CT and MR technology.
We look forward to the progress set forth in
his and future ACC/Duke imaging quality think
anks. It is an interesting time in cardiac imaging,
ith a wealth of available data and exciting new
evelopments in molecular, vascular wall, and
-dimensional imaging. However, this is a time
hen all relevant and interested parties—private
ractice and academic imagers, industry, the Na-
ional Institutes of Health, the Food and Drug
dministration, and public and private payers—
ust all coalesce toward the same goal of devising
igh-quality standards for quality cardiac imaging.
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